What Does the Published Research Say About ARA‑290 (cibinetide)?

Research Context

• Scope: This summary is limited to the sources in the synthesis packet and separates direct human evidence, review-context literature, and preclinical/mechanistic findings. Citation markers refer to the supplied items (e.g., [pubmed:29392190]).
• Evidence map (from the packet): 1 human-source item, 3 review items, and 8 preclinical or related items. The strongest conclusions should remain tied to the specific human context studied.

Key Takeaway

Human evidence for ARA‑290 (cibinetide) is limited and neuropathy-focused. Most reported effects come from preclinical models; mechanism centers on innate repair receptor (IRR) engagement, which does not by itself establish clinical efficacy.

Direct Answer

• Direct human-source evidence exists but is narrow and neuropathy-focused; conclusions should remain anchored to the specific populations, endpoints, and disease contexts actually studied [pubmed:29392190].
• Mechanistically, ARA‑290 targets the innate repair receptor (IRR), a heteromer of the erythropoietin receptor and the β‑common (CD131) receptor, with signaling linked to anti‑inflammatory and tissue‑repair pathways [pubmed:29392190].
• Reviews provide mechanistic and translational framing but do not substitute for primary human outcome data [pubmed:39996752; pubmed:28652140; pubmed:33423557].
• Multiple preclinical studies report model‑specific effects (e.g., neuroinflammation, ischemia, nerve injury, SLE, chemotherapy‑related genotoxicity), which should not be presented as established human outcomes [pubmed:29570934; pubmed:36046815; pubmed:38488446; pubmed:40216181; pubmed:32335150].
• Dosing, safety, and broad clinical recommendations are not established by the supplied sources (packet uncertainties).

Direct Human Evidence

• The packet includes a single human‑source citation focused on neuropathy that characterizes the IRR as a heteromer of EPOR and the β‑common (CD131) receptor and links its activation to anti‑inflammatory and tissue‑repair signaling [pubmed:29392190].
• Importantly, this item primarily functions as review/context rather than reporting primary trial outcomes. It contains the packet’s only human‑level information and should not be overinterpreted as robust clinical efficacy evidence. Conclusions should not be generalized beyond the studied neuropathy context and endpoints [pubmed:29392190].

Review Literature and Context

• Reviews in the packet summarize erythropoietin biology and related translational topics, providing context but not primary outcome evidence:
• Erythropoietin’s canonical role in erythropoiesis and broader regulatory considerations are covered in overviews [pubmed:39996752; pubmed:28652140]. These reviews are not specific to ARA‑290 clinical outcomes.
• The translational challenges and unmet need in neuropathy are reviewed, relevant to considering targets like IRR/ARA‑290 [pubmed:33423557].
• These reviews help frame mechanistic plausibility and clinical rationale but do not establish clinical efficacy [pubmed:39996752; pubmed:28652140; pubmed:33423557].

Preclinical and Mechanistic Findings (Animal/In Vitro)

• ARA‑290‑specific models:
• Murine chronic stress: ARA‑290 ameliorated depression‑like behavior and reduced inflammation in mice [pubmed:36046815].
• Murine cerebral ischemia: ARA‑290 mediated brain tissue protection via the β‑common receptor in a stroke model [pubmed:38488446].
• Schwann cell/sciatic nerve injury (preclinical, 2025): ARA‑290 inhibited NLRP3 inflammasome activation in Schwann cells after sciatic nerve injury [pubmed:40216181].
• Chemotherapy injury (preclinical): ARA‑290 attenuated doxorubicin‑induced genotoxicity and oxidative stress in experimental systems [pubmed:32335150].
• EPO‑derived peptide models not necessarily specifying ARA‑290:
• Systemic lupus erythematosus (murine): a non‑erythropoietic EPO‑derived peptide protected mice in an SLE model [pubmed:29570934].
• Important caveat: These findings are model‑ and context‑specific. They provide mechanistic hypotheses and translational signals but do not establish human clinical efficacy.

Peripheral or Reference Materials in the Packet

• General reference resources: a PubChem compound record for cibinetide and a patent‑search entry are listed for background/reference and do not substantiate delivery, stability, or design claims [pubchem:91810664; patent_search:ara-290-cibinetide-helix-b-surface-peptide].
• Peptide/helix design references provide general background on peptide architectures and are not ARA‑290 clinical or delivery studies [crossref:10.1007/springerreference_35417; crossref:10.1007/springerreference_33352; crossref:10.1007/3-540-29623-9_7284; crossref:10.1021/ja061989d.s001; crossref:10.1021/jacs.5c04078.s001].
• Other packet items with peripheral relevance and not directly focused on ARA‑290 include a delivery system for pain relief in experimental neuropathy [pubmed:27028159], a bioengineered nanoreactor for radiation‑induced lung injury [pubmed:34478930], and a review on macrophage efferocytosis in apical periodontitis [pubmed:38612664]. These do not provide direct clinical evidence for ARA‑290.

What Is Not Established (Explicit Cautions)

• Clinical efficacy beyond the specific human populations and endpoints actually studied is not supported by this packet [pubmed:29392190].
• Translation of preclinical findings to human outcomes is uncertain; animal/in vitro results should not be reframed as proven clinical efficacy [pubmed:29570934; pubmed:36046815; pubmed:38488446; pubmed:40216181; pubmed:32335150].
• Dosing, safety, and generalized clinical recommendations are not established by the supplied sources (packet uncertainties).
• Broad claims (e.g., anti‑aging; generalized tissue repair across indications) are unsupported by the present evidence base; mechanistic plausibility alone does not establish clinical utility (packet unsupported claims).

Practical Notes for Researchers

• The literature in this packet is review‑heavy relative to primary human studies; prioritize primary human outcome data when forming clinical or regulatory conclusions.
• Preclinical signals highlight mechanistic axes (IRR signaling via β‑common/CD131; inflammasome modulation; anti‑inflammatory and tissue‑protective phenotypes) that may justify targeted translational studies. Each requires clinical validation before therapeutic claims are made [pubmed:29392190; pubmed:36046815; pubmed:38488446; pubmed:40216181; pubmed:32335150].

FAQ

• What is ARA‑290 (cibinetide) and how is it thought to work?
• It is a non‑erythropoietic erythropoietin‑derived peptide that targets the innate repair receptor (IRR), a heteromer of EPOR and β‑common (CD131), linked to anti‑inflammatory and tissue‑repair signaling [pubmed:29392190].
• What human evidence exists for ARA‑290?
• The packet contains one neuropathy‑focused human‑source item that primarily serves as review/context with limited human‑level information; it should not be treated as robust clinical efficacy evidence [pubmed:29392190].
• What do preclinical studies suggest?
• Model‑specific signals include effects in murine depression‑like behavior, murine cerebral ischemia, Schwann cell inflammasome modulation after nerve injury, and attenuation of doxorubicin‑related genotoxicity [pubmed:36046815; pubmed:38488446; pubmed:40216181; pubmed:32335150]. These are not established human outcomes.
• Do the reviews in the packet demonstrate clinical efficacy for ARA‑290?
• No. They provide mechanistic and translational context (e.g., EPO biology, neuropathy unmet needs) and do not establish ARA‑290 clinical outcomes [pubmed:39996752; pubmed:28652140; pubmed:33423557].
• Does the packet support dosing or safety conclusions for ARA‑290?
• No. Dosing, safety, and broad clinical recommendations are not established by the supplied sources (packet uncertainties).

References

• [pubmed:29392190] Targeting the innate repair receptor to treat neuropathy. https://pubmed.ncbi.nlm.nih.gov/29392190/
• [pubmed:39996752] The Role of Erythropoietin in Metabolic Regulation. https://pubmed.ncbi.nlm.nih.gov/39996752/
• [pubmed:28652140] Erythropoietin in diabetic retinopathy. https://pubmed.ncbi.nlm.nih.gov/28652140/
• [pubmed:33423557] The time to develop treatments for diabetic neuropathy. https://pubmed.ncbi.nlm.nih.gov/33423557/
• [pubmed:29570934] Non‑erythropoietic erythropoietin‑derived peptide protects mice from systemic lupus erythematosus. https://pubmed.ncbi.nlm.nih.gov/29570934/
• [pubmed:36046815] Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress‑Induced Depression‑Like Behavior and Inflammation in Mice. https://pubmed.ncbi.nlm.nih.gov/36046815/
• [pubmed:38488446] Erythropoietin‑derived peptide ARA290 mediates brain tissue protection through the β‑common receptor in mice with cerebral ischemic stroke. https://pubmed.ncbi.nlm.nih.gov/38488446/
• [pubmed:40216181] ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury. https://pubmed.ncbi.nlm.nih.gov/40216181/
• [pubmed:32335150] An engineered non‑erythropoietic erythropoietin‑derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. https://pubmed.ncbi.nlm.nih.gov/32335150/
• [pubchem:91810664] PubChem compound record: Cibinetide. https://pubchem.ncbi.nlm.nih.gov/compound/91810664
• [patent_search:ara-290-cibinetide-helix-b-surface-peptide] Google Patents search for ARA‑290 cibinetide helix B surface peptide. https://patents.google.com/?q=ARA-290+cibinetide+helix+B+surface+peptide
• [crossref:10.1007/springerreference_35417] Helix Initiation Peptide Helix Termination Peptide. https://doi.org/10.1007/springerreference_35417
• [crossref:10.1007/springerreference_33352] Helix Termination Peptide. https://doi.org/10.1007/springerreference_33352
• [crossref:10.1007/3-540-29623-9_7284] Helix Initiation Peptide Helix Termination Peptide (2005). https://doi.org/10.1007/3-540-29623-9_7284
• [crossref:10.1021/ja061989d.s001] Helix Triangle: Unique Peptide‑Based Molecular Architecture. https://doi.org/10.1021/ja061989d.s001
• [crossref:10.1021/jacs.5c04078.s001] Metal‑‑Helix Peptide Frameworks. https://doi.org/10.1021/jacs.5c04078.s001
• [pubmed:27028159] Mesoporous Silica Particles as a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy. https://pubmed.ncbi.nlm.nih.gov/27028159/
• [pubmed:34478930] Multifaceted roles of a bioengineered nanoreactor in repressing radiation‑induced lung injury. https://pubmed.ncbi.nlm.nih.gov/34478930/
• [pubmed:38612664] The Role of Macrophage Efferocytosis in the Pathogenesis of Apical Periodontitis. https://pubmed.ncbi.nlm.nih.gov/38612664/